DRUG NEWS: FDA moves to control label changes

May 2005 
Volume 35  Number 5
Pages 30 - 30
  PDF Version Available!

© 2005 Lippincott Williams & Wilkins, Inc. Volume 35(5)             May 2005             p 30 FDA moves to control label changes [DRUG NEWS: ADVERSE DRUG REACTIONS]

The FDA petitioned Congress for the authority to dictate drug label changes. Currently, the FDA has to negotiate with drug companies about changes, which can delay warnings to the public.

At a congressional committee hearing, Sandra L. Kweder, FDA deputy director for new drugs, testified that a public warning about the dangers of rofecoxib (Vioxx) was delayed because the FDA had to haggle with the drug's manufacturer, Merck & Co., about the language. Merck pulled Vioxx from the market in September because some patients taking the drug developed serious cardiac problems.

Under a new policy, the Bush administration has endorsed announcing warnings to the public before label changes are finalized. Congress is also considering ...

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

Featured Jobs

Benefits of Membership

FREE E-Newsletters
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues

Join our CESaver program to earn up to 100 contact hours for only $34.95
Register Now

Lippincott's NursingCenter.com
Explore a world of online resources

Become a Member